AUTHOR SUMMARY
The protein actin is a component of the cytoskeleton in eukaryotic cells. Cells accomplish many tasks by dynamically rearranging the actin cytoskeleton (e.g., establishing polarity, moving in a directed fashion, interacting with adjacent cells and the extracellular matrix, and importing materials from the environment and transporting them internally). All of these processes require polymerization of actin from a soluble pool into polarized filaments at specific places and times in response to collections of incoming signals (1) . In many cases, actin polymerization is spatially and temporally controlled by specific factors that nucleate new actin filaments. One such factor is the ubiquitous Arp2/ 3 complex, which nucleates new actin filaments from the sides of existing filaments. Inactive in isolation, the Arp2/3 complex can be activated by association with members of the WiskottAldrich syndrome protein (WASP) family (2) . After a decade of study, the mechanism by which members of the WASP family stimulate the Arp2/3 complex to nucleate new filaments is still only partially understood. In this study, we use an integrated biochemical and biophysical approach to arrive at a model for interactions between WASP and the Arp2/3 complex during nucleation (Fig. 1) .
The Arp2/3 complex is composed of seven protein subunits. Two subunits are actin-related proteins for which the complex is named, Arp2 and Arp3. These are thought to participate directly in the nucleation of new actin filaments. Actin nucleation by the Arp2/3 complex is greatly stimulated by a conserved C-terminal element that defines the WASP family, the VCA. The VCA is so named for its V region, a central region and an acidic region, the latter of which together constitute the CA region. The CA region binds the Arp2/3 complex and triggers a conformational change thought to be necessary for nucleation. In addition to this conformational change and actin delivery, which is facilitated by the V region, the Arp2/3 complex must also bind to an existing actin filament for nucleation to occur.
Despite its importance, the structural basis of the VCAArp2/3 complex interaction has been difficult to elucidate. To date, a high-resolution X-ray crystal structure that would reveal these contacts in detail has not been identified. Studies using a variety of methods, such as chemically introducing covalent bonds between the VCA and nearby Arp2/3 complex subunits, have identified more than half of the subunits of the Arp2/3 complex as potential VCA binding sites. However, these reports have been difficult to merge into a coherent structural model of how a VCA peptide binds to the Arp2/3 complex. For example, the acidic portion of the CA region has been independently reported to bind two subunits of the Arp2/3 complex, but these subunits are far apart in both the inhibited Arp2/3 complex crystal structure (3) and the three dimensional reconstruction of the Arp2/3 complex in the actin filament branch junction determined through the use of electron microscopy (4). Similarly, while it is clear that the delivery of an actin monomer is important, whether the actin monomer is first delivered to Arp2 or Arp3 is still debated.
Resolving where the CA region binds the Arp2/3 complex and where the first actin monomer is delivered are essential components of a mechanistic description of nucleation.
Models stemming from these studies have implicitly assumed that one VCA delivers one actin to the Arp2/3 complex to trigger nucleation. However, we recently showed that dimerization substantially increases the activity of WASPfamily VCA domains, which suggests that multiple VCA binding sites exist on the Arp2/3 complex (5). This observation raised several questions: How many VCA peptides independently bind to the Arp2/3 complex, and if more than one, what are their distinct functions? How many actin monomers do VCA peptides deliver to Arp2/3 complex? Fig. P1 . The nucleation of new actin filaments is a tightly regulated process. The actin nucleation factor, Arp2/3 complex is a sevenmembered protein machine (shown as a multicolored assembly, with subunit names indicated in black lettering). Arp2/3 complex is activated by VCA peptides (indicated in black) of the WASP family of proteins. Described in this study is a structural model of the nucleation process, in which two of these peptides deliver two actin monomers (in gray) to Arp2/3 complex. Here, we employed an integrated biochemical-biophysical approach to resolve these questions. Using analytical ultracentrifugation methods, we found that two VCA peptides bind the Arp2/3 complex simultaneously, and by adding a distinct competing Arp2/3 complex ligand-the acidic domain from the N terminus of the protein Cortactin (NtA)-we determined that these two binding sites are not equivalent. In the presence of excess Cortactin NtA, only one VCA binds to the Arp2/3 complex, providing a useful tool to distinguish between the two binding sites. Site-specific incorporation of cross-linking and label transfer reagents into CA peptides, and competition with the site-discriminating Cortactin NtA domain, allowed us to resolve the CA peptide contacts with the Arp2/3 complex into two separate binding sites: one site contacting Arp2 and the other site contacting Arp3.
Additional experiments revealed that both VCA peptides can accommodate actin while bound to Arp2/3 complex, and that covalent VCA heterodimers lacking one of the two actin delivering V regions have very low activity. The activity of covalent VCA dimers sharply decreases when the separation of their N termini drops below 70 Å, suggesting that there is a critical separation distance for N-terminal V regions. Tandem VCA dimers, connected head-to-tail as a single polypeptide, bind the Arp2/3 complex asymmetrically in the presence of actin. Using these engineered VCA materials, we showed that actin delivery to Arp3 likely serves a more important role in nucleation, while delivery to Arp2 enhances affinity. Together these data suggest that two actin monomers must be delivered to the Arp2/3 complex for high-potency activation. We propose that nucleation proceeds through an assembly of two VCAs, two actin monomers, and one Arp2/3 complex. Finally, we propose a structural model for this assembly based on the combined literature, our new observation regarding stoichiometry of the assembly, and our site-specific crosslinking data.
Our structural model describes both VCA-binding sites on the Arp2/3 complex. One VCA binding site has the CA element engaged with conserved surfaces on Arp2 and an adjacent subunit, ArpC1, with its V region positioned for delivery of actin to Arp2. The other VCA-binding site has the CA peptide engaged with conserved surfaces on Arp3 and its V region positioned for delivery of actin to Arp3. This model makes testable predictions regarding the activity of engineered VCA dimers. The spatial organization of the N termini of the V regions predicts sensitivity to the length of the linker that connects them, which was observed by varying the number of disordered residues linking the two V regions. The difference between the spacing of N termini at one site and the C termini of the VCA bound to the other site suggests that tandem VCA dimers bound to actin can only activate the Arp2/3 complex when bound in one orientation, as we observed in label transfer experiments. Thus, our model explains both of these additional observations.
In cells, WASP proteins integrate a wide variety of signals to control Arp2/3 complex-mediated actin dynamics. These signals include lipids and protein ligands, which cooperate to cluster WASP proteins at membranes. Our model of VCA binding to Arp2/3 complex has interesting implications in this regard. First, VCA dimers are likely the functional form of WASP proteins in cells, reinforcing a biochemical mechanism in which two VCAs act together to promote nucleation. Until recently, the regulation of VCA activity has been almost exclusively cast in terms of the action of individual WASP proteins and allosteric mechanisms that control access to VCAs. The model we present here proposes that the Arp2/3 complex is usually bound by two WASP proteins during activation, and thus activation of WASP proteins by oligomerization is part of their normal functioning. Second, the cellular mechanisms of WASP signal integration appear to have coevolved with the molecular mechanism of Arp2/3 complex activation, illustrating the ability of different organizational scales to influence one another. We hope that this mechanistic insight into the Arp2/3 complex function will drive both biochemical and biological studies of actin dynamics.
